FDG-Avid But FAPI-Negative Intramucosal Carcinoma in a Colorectal Adenoma.

Clin Nucl MedMay 11, 2026 (epub)
Case ReportGastroenterologyOncology (Medical)

Shinobu Adaniya, Masao Murakami, Toshimitsu Momose

✦ AI-curated · Sources linked

Case in brief

A man in his 70s presented for follow-up of hepatocellular carcinoma, undergoing both FDG PET/CT and 18F FAPI-74 PET/CT. The FDG PET revealed intense focal uptake in the sigmoid colon, while the FAPI PET showed no abnormal uptake. Endoscopic resection confirmed carcinoma in adenoma confined to the lamina propria, indicating a lack of desmoplastic reaction.

What made this case unusual

The case highlights a significant discrepancy between FDG and FAPI PET findings, with FDG showing uptake in an early-stage carcinoma while FAPI did not, suggesting limitations of FAPI in detecting intramucosal lesions.

Diagnostic / clinical pearl

Clinicians should be aware that FAPI PET may not be reliable for detecting early intramucosal carcinomas, particularly in adenoma-dominant lesions.

Why it matters

Understanding the limitations of FAPI PET in early colorectal lesions is crucial for accurate diagnosis and management, especially in cases where FDG PET indicates potential malignancy.

Source

PubMed · PMID 42148857

Published in Clin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.